Any current/future capex/capital investment/strategic investment?

Planned capex of around INR 105-120 crores in Q1 FY'25, mainly for Module E at the Lote Parshuram site. Majority of this capex funded from IPO proceeds. Module E is a new dedicated production block with ~350 KL capacity, expected operational by Q1 FY'25. Ambernath greenfield site refurbished for bottling activities and API R&D; operational also by Q1 FY'25. Additional INR 60 crores capex over the next two years planned for Ambernath site to support CDMO/CMO activities, especially anaesthetic product bottling. Refurbishment planned for older modules (ABC) in the next fiscal. Capex e

Future growth expectations in sales/revenue/volumes?

Supriya Lifescience aims to achieve INR 1,000 crores+ revenue by FY'27, driven by existing products, new product launches, and CDMO/CMO business. Sustained year-on-year revenue growth of 20%-23% is targeted over the next three years. Contribution from CMO/CDMO, especially the anaesthetic product (a $300 million global market), is expected to be significant and could exceed conservative projections. Existing top products are growing at 5%-10%, with some products growing at around 8%-10%. Addition of 4-5 new products annually via enhanced R&D. Europe sales have increased substantially, indicatin

Future growth expectations in earnings/operating earnings/profits/EPS?

Supriya Lifescience expects revenue growth of around 20% annually over the next three years. The company aims to achieve INR 1,000 crores revenue by FY'27, driven by existing products and new launches. Sustainable EBITDA margins are guided between 28%-30%, expected to be stable across quarters. Some individual projects, especially in CDMO/CMO, may have higher margins but blended portfolio margin guidance remains conservative. Profit before tax grew around 217% in Q3 FY24 compared to Q3 FY23; PAT margin improved to 21.6%. Continued product launches and expansion, including module E and Ambernat

Current/ Expected Orderbook/ Pending Orders?

Supriya Lifescience has received the first commercial order from DSM Firmenich and has a good forecast for the next financial year. The DSM Firmenich contract at full capacity has an estimated potential of INR 60-70 crores. Advanced-level discussions are ongoing for bottling anesthetic products at the new Ambernath facility. No concrete CDMO/CMO orders are currently finalized for Ambernath; utilization ramp-up expected over 2-3 years due to regulatory inspections. Whey protein project recently completed equipment installation; trial batches supplied to distributors with plans to commercialize

Supriya Lifesci.Q3 FY24Pharmaceuticals & Biotechnology

Supriya Lifesci. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹931P/E: 39.9Market Cap: ₹7.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Supriya Lifescience aims to achieve INR 1,000 crores+ revenue by FY'27, driven by existing products, new product launches, and CDMO/CMO business.
Sustained year-on-year revenue growth of 20%-23% is targeted over the next three years.
Contribution from CMO/CDMO, especially the anaesthetic product (a $300 million global market), is expected to be significant and could exceed conservative projections.
Existing top products are growing at 5%-10%, with some products growing at around 8%-10%.
Addition of 4-5 new products annually via enhanced R&D.
Europe sales have increased substantially, indicating improved traction in regulated markets like Europe and North America.
Capacity expansion (including new module E with 350 KL added capacity) will double overall capacity, supporting volume growth.
New product categories include anaesthetics, anti-diabetic, and anti-anxiety therapies.

Margin guidance

Category 3

Supriya Lifescience expects revenue growth of around 20% annually over the next three years.
The company aims to achieve INR 1,000 crores revenue by FY'27, driven by existing products and new launches.
Sustainable EBITDA margins are guided between 28%-30%, expected to be stable across quarters.
Some individual projects, especially in CDMO/CMO, may have higher margins but blended portfolio margin guidance remains conservative.
Profit before tax grew around 217% in Q3 FY24 compared to Q3 FY23; PAT margin improved to 21.6%.
Continued product launches and expansion, including module E and Ambernath facility, will support growth.
CDMO business launch expected to enhance revenues, though initial utilization may ramp up over 2-3 years.
Management maintains a cautious but optimistic approach, focusing on diversified markets and sustainable margin profile.

See what Supriya Lifesci. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

- The company plans capex of around INR100-120 crores for Module E at the Parshuram plant, mostly funded from IPO proceeds, indicating no immediate equity raise for this. - Additional capex of about INR60 crores is planned for Ambernath site expansion with environment clearance. - For the current fiscal year (FY24), capex is expected at around INR105-110 crores, and a similar amount is planned for FY25. - There is no explicit mention of any new fundraising through debt or equity in the near term. - The company appears to be funding expansions primarily through internal accruals and existing IPO proceeds. Summary: No new debt or equity fundraising is indicated currently; expansions are being funded largely through IPO proceeds and internal funds.

Order book

Yes

Supriya Lifescience has received the first commercial order from DSM Firmenich and has a good forecast for the next financial year.
The DSM Firmenich contract at full capacity has an estimated potential of INR 60-70 crores.
Advanced-level discussions are ongoing for bottling anesthetic products at the new Ambernath facility.
No concrete CDMO/CMO orders are currently finalized for Ambernath; utilization ramp-up expected over 2-3 years due to regulatory inspections.
Whey protein project recently completed equipment installation; trial batches supplied to distributors with plans to commercialize by Q2 FY'25.
New product registrations and filings are progressing, boosting future order prospects.
Overall, order visibility is strengthening with expanding contracts and promising pipeline in both API and CDMO segments.

See what Supriya Lifesci. management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned capex of around INR 105-120 crores in Q1 FY'25, mainly for Module E at the Lote Parshuram site.
Majority of this capex funded from IPO proceeds.
Module E is a new dedicated production block with ~350 KL capacity, expected operational by Q1 FY'25.
Ambernath greenfield site refurbished for bottling activities and API R&D; operational also by Q1 FY'25.
Additional INR 60 crores capex over the next two years planned for Ambernath site to support CDMO/CMO activities, especially anaesthetic product bottling.
Refurbishment planned for older modules (ABC) in the next fiscal.
Capex expansion is modular and phased, aligned with utilization and orders.
Asset turns target of 2.5x and above from this capex.
Expansion aims to support revenue growth to INR 1,000 crores by FY'27 and strengthen backward integration and new product launches.

Track Supriya Lifesci. — get its next earnings analysis in your feed

How does Supriya Lifesci. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSupriya Lifesci.

Rev 2Mar 3

See where Supriya Lifesci. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Supriya Lifesci. rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifesci. against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Supriya Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →